^
    Back
    Association details:
    Biomarker:BCL2 expression
    Cancer:Hodgkin Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 6235: BCL2 blockade in refractory and relapsed classic Hodgkin Lymphoma; Venetoclax sensitize cells to first line treatment

    Published date:
    05/15/2020
    Excerpt:
    L1236, U-H01, KM-H2, SUPDH1 and L540 human cHL cell lines that express BCL2 protein, were sensitive to venetoclax a specific BCL2 inhibitor.
    DOI:
    10.1158/1538-7445.AM2020-6235